From each FDA label

Do GLP-1s cause low blood sugar?

10 of the 10 current GLP-1 labels carry a warning on low blood sugar. Wegovy's label says: "Wegovy lowers blood glucose and can cause hypoglycemia."

Read from each manufacturer's FDA label on DailyMed. The newest revision saying anything on this is Aug 28, 2026.

Word for word

What each label says about low blood sugar

Sentences from each label's warnings and side effect sections. Only cross-references are removed.

Wegovy · Warning: Hypoglycemia

Wegovy lowers blood glucose and can cause hypoglycemia.
In a trial of Wegovy injection in adult patients with type 2 diabetes and body mass index (BMI) greater than or equal to 27 kg/m 2 for weight reduction (Study 3), hypoglycemia (defined as a plasma glucose less than 54 mg/dL) was reported in more patients treated with Wegovy versus placebo.
One episode of severe hypoglycemia (requiring the assistance of another person) was reported in one Wegovy treated patient versus no placebo-treated patients.
In a trial of adult patients with type 2 diabetes and BMI greater than or equal to 27 kg/m 2 for weight reduction, clinically significant hypoglycemia (defined as a plasma glucose less than 54 mg/dL) was reported in 6.2% of Wegovy injection-treated patients versus 2.5% of placebo-treated patients.

Label revised Jun 18, 2026. DailyMed

Ozempic · Warning: Hypoglycemia with Concomitant Use of Insulin Secretagogues or Insulin

Patients receiving Ozempic in combination with an insulin secretagogue (e.g., sulfonylurea) or insulin may have an increased risk of hypoglycemia, including severe hypoglycemia.
The risk of hypoglycemia may be lowered by a reduction in the dose of sulfonylurea (or other concomitantly administered insulin secretagogue) or insulin.
Inform patients using these concomitant medications of the risk of hypoglycemia and educate them on the signs and symptoms of hypoglycemia.
Severe hypoglycemia occurred in 0.8% and 1.2% of patients when Ozempic 0.5 mg and 1 mg, respectively, was coadministered with a sulfonylurea.

Label revised Jun 1, 2026. DailyMed

Rybelsus and Ozempic tablets · Warning: Hypoglycemia with Concomitant Use of Insulin Secretagogues or Insulin

Patients receiving Rybelsus or Ozempic tablets in combination with an insulin secretagogue (e.g., sulfonylurea) or insulin may have an increased risk of hypoglycemia, including severe hypoglycemia.
The risk of hypoglycemia may be lowered by a reduction in the dosage of sulfonylurea (or other concomitantly administered insulin secretagogue) or insulin.
Inform patients using these concomitant medications of the risk of hypoglycemia and educate them on the signs and symptoms of hypoglycemia.
In the pool of placebo- and active-controlled trials, the types and frequency of common adverse reactions, excluding hypoglycemia, were similar to those listed in Table 2.

Label revised Jan 30, 2026. DailyMed

Zepbound · Warning: Hypoglycemia

Zepbound lowers blood glucose and can cause hypoglycemia.
In a trial of patients with type 2 diabetes mellitus and BMI ≥27 kg/m 2 (Study 2), hypoglycemia (plasma glucose <54 mg/dL) was reported in 4.2% of Zepbound-treated patients versus 1.3% of placebo-treated patients.
In this trial, patients taking Zepbound in combination with an insulin secretagogue (e.g., sulfonylurea) had increased risk of hypoglycemia (10.3%) compared to Zepbound-treated patients not taking a sulfonylurea (2.1%).
In Study 2, a trial of patients with type 2 diabetes mellitus and BMI ≥27 kg/m 2, hypoglycemia (plasma glucose <54 mg/dL) was reported in 4.2% of Zepbound-treated patients versus 1.3% of placebo-treated patients.

Label revised Aug 28, 2026. DailyMed

Mounjaro · Warning: Hypoglycemia with Concomitant Use of Insulin Secretagogues or Insulin

Patients receiving Mounjaro in combination with an insulin secretagogue (e.g., sulfonylurea) or insulin may have an increased risk of hypoglycemia, including severe hypoglycemia.
The risk of hypoglycemia may be lowered by a reduction in the dose of sulfonylurea (or other concomitantly administered insulin secretagogue) or insulin.
Inform patients using these concomitant medications of the risk of hypoglycemia and educate them on the signs and symptoms of hypoglycemia.
In an adult clinical trial up to 104 weeks of treatment, when administered with a sulfonylurea, hypoglycemia (glucose level <54 mg/dL) occurred in 13.8%, 9.9%, and 12.8%, and severe hypoglycemia occurred in 0.5%, 0%, and 0.6% of patients treated with Mounjaro 5 mg, 10 mg, and 15 mg, respectively.

Label revised Aug 27, 2026. DailyMed

Foundayo · Warning: Hypoglycemia

Foundayo lowers blood glucose and can cause hypoglycemia.
In a trial of adults with type 2 diabetes and BMI ≥27 kg/m 2 (Trial 2), hypoglycemia (plasma glucose <54 mg/dL) was reported in 2% of patients treated with orforglipron versus 0.2% of patients receiving placebo.
One patient treated with orforglipron and no patients receiving placebo reported severe hypoglycemia in Trial 2.
In Trial 2, a trial of patients with type 2 diabetes and BMI ≥27 kg/m 2, hypoglycemia (glucose <54 mg/dL) was reported in 2% of Foundayo-treated patients versus 0.2% of placebo-treated patients.

Label revised Jul 29, 2026. DailyMed

Trulicity · Warning: Hypoglycemia with Concomitant Use of Insulin Secretagogues or Insulin

Patients receiving Trulicity in combination with an insulin secretagogue (e.g., sulfonylurea) or insulin may have an increased risk of hypoglycemia, including severe hypoglycemia.
The risk of hypoglycemia may be lowered by a reduction in the dose of sulfonylurea (or other concomitantly administered insulin secretagogue) or insulin.
Inform patients using these concomitant medications of the risk of hypoglycemia and educate them on the signs and symptoms of hypoglycemia.
In a 78-week adult clinical trial, hypoglycemia (glucose level <54 mg/dL) occurred in 20% and 21% of patients when Trulicity 0.75 mg and 1.5 mg, respectively, were co-administered with a sulfonylurea.

Label revised Jun 16, 2026. DailyMed

Saxenda · Warning: Hypoglycemia

Adult patients with type 2 diabetes mellitus on an insulin secretagogue (e.g., sulfonylurea) or insulin may have an increased risk of hypoglycemia with use of Saxenda, including severe hypoglycemia.
In patients with type 2 diabetes, monitor blood glucose prior to starting Saxenda and during Saxenda treatment.
The risk of hypoglycemia may be lowered by a reduction in the dose of sulfonylurea (or other concomitantly administered insulin secretagogues) or insulin.
In a clinical trial in adult patients with type 2 diabetes mellitus and overweight (excess weight) or obesity, severe hypoglycemia (defined as requiring the assistance of another person) occurred in 3 (0.7%) of 422 Saxenda-treated patients (all taking a sulfonylurea) and in none of the 212 placebo-treated patients. In this trial, among patients taking a sulfonylurea, hypoglycemia defined as a plasma glucose less than 54 mg/dL with or without symptoms occurred in 31 (28.2%) of 110 Saxenda-treated patients and 7 (12.7%) of 55 placebo-treated patients.

Label revised Feb 25, 2026. DailyMed

Victoza · Warning: Hypoglycemia

Adult patients receiving Victoza in combination with an insulin secretagogue (e.g., sulfonylurea) or insulin may have an increased risk of hypoglycemia, including severe hypoglycemia.
In pediatric patients 10 years of age and older, the risk of hypoglycemia was higher with Victoza regardless of insulin and/or metformin use..
The risk of hypoglycemia may be lowered by a reduction in the dose of sulfonylurea (or other concomitantly administered insulin secretagogues) or insulin.
In a 26-week placebo-controlled clinical trial in pediatric patients 10 years of age and older with a 26-week open-label extension, 21.2% of Victoza-treated patients (mean age 14.6 years) with type 2 diabetes mellitus, had hypoglycemia with a blood glucose <54 mg/dL with or without symptoms (335 events per 1,000 patient years).

Label revised Oct 14, 2025. DailyMed

Byetta · Warning: Hypoglycemia with Concomitant Use of Insulin Secretagogues or Insulin

Patients receiving Byetta in combination with an insulin secretagogue (e.g., sulfonylurea) or insulin may have an increased risk of hypoglycemia including severe hypoglycemia.
The risk of hypoglycemia may be lowered by a reduction in the dose of sulfonylurea (or other concomitantly administered insulin secretagogue) or insulin.
Inform patients using these concomitant medications of the risk of hypoglycemia and educate them on the signs and symptoms of hypoglycemia.
For the 24-week placebo-controlled study of Byetta used as a monotherapy, Table 2 summarizes adverse reactions (excluding hypoglycemia) occurring with an incidence ≥2% and occurring more frequently in Byetta-treated patients compared with placebo-treated patients.

Label revised Sep 2, 2025. DailyMed

Not from trials

Reports to FDA about low blood sugar

Counts of voluntary reports from patients and doctors. They cannot show that a medicine caused anything and cannot give a rate, and a brand used by more people draws more reports.

Medicine	Reports naming	All reports on it
Byetta	Blood glucose decreased: 5,557 · Hypoglycaemia: 683	52,087
Trulicity	Blood glucose decreased: 1,818 · Hypoglycaemia: 501	87,279
Ozempic	Blood glucose decreased: 1,224 · Hypoglycaemia: 388	70,863
Victoza	Blood glucose decreased: 1,143 · Hypoglycaemia: 381	41,462
Mounjaro	Blood glucose decreased: 1,020 · Hypoglycaemia: 659	97,440
Zepbound	Blood glucose decreased: 201 · Hypoglycaemia: 107	80,835
Rybelsus and Ozempic tablets	Blood glucose decreased: 134 · Hypoglycaemia: 59	7,758
Wegovy	Blood glucose decreased: 123 · Hypoglycaemia: 111	25,993
Saxenda	Blood glucose decreased: 65 · Hypoglycaemia: 38	7,270
Foundayo	Blood glucose decreased: 12 · Hypoglycaemia: 6	3,050

Counted through openFDA from FDA's Adverse Event Reporting System, refreshed weekly. One report can name several terms.

Updated automatically

Latest FDA label updates

Aug 28, 2026FDA labelFDA label updated: Zepbound (Eli Lilly and Company), effective 2026-08-28
Aug 27, 2026FDA labelFDA label updated: Mounjaro (Eli Lilly and Company), effective 2026-08-27
Jul 29, 2026FDA labelFDA label updated: Foundayo (Eli Lilly and Company), effective 2026-07-29
Jul 27, 2026FDA labelFDA label updated: Liraglutide (Meitheal Pharmaceuticals Inc.), effective 2026-07-27
Jun 24, 2026FDA labelFDA label updated: Liraglutide (NorthStar Rx LLC), effective 2026-06-24

Written from each source's own record as it changes. Every change on GLPcompare

Questions

Low blood sugar on a GLP-1: common questions

Does Wegovy cause low blood sugar?

Its FDA label: Wegovy lowers blood glucose and can cause hypoglycemia. In a trial of Wegovy injection in adult patients with type 2 diabetes and body mass index (BMI) greater than or equal to 27 kg/m 2 for weight reduction (Study 3), hypoglycemia (defined as a plasma glucose less than 54 mg/dL) was reported in more patients treated with Wegovy versus placebo.

Does Ozempic cause low blood sugar?

Its FDA label: Patients receiving Ozempic in combination with an insulin secretagogue (e.g., sulfonylurea) or insulin may have an increased risk of hypoglycemia, including severe hypoglycemia. The risk of hypoglycemia may be lowered by a reduction in the dose of sulfonylurea (or other concomitantly administered insulin secretagogue) or insulin.

Does Rybelsus cause low blood sugar?

Its FDA label: Patients receiving Rybelsus or Ozempic tablets in combination with an insulin secretagogue (e.g., sulfonylurea) or insulin may have an increased risk of hypoglycemia, including severe hypoglycemia. The risk of hypoglycemia may be lowered by a reduction in the dosage of sulfonylurea (or other concomitantly administered insulin secretagogue) or insulin.

Does Zepbound cause low blood sugar?

Its FDA label: Zepbound lowers blood glucose and can cause hypoglycemia. In a trial of patients with type 2 diabetes mellitus and BMI ≥27 kg/m 2 (Study 2), hypoglycemia (plasma glucose <54 mg/dL) was reported in 4.2% of Zepbound-treated patients versus 1.3% of placebo-treated patients.

Does Mounjaro cause low blood sugar?

Its FDA label: Patients receiving Mounjaro in combination with an insulin secretagogue (e.g., sulfonylurea) or insulin may have an increased risk of hypoglycemia, including severe hypoglycemia. The risk of hypoglycemia may be lowered by a reduction in the dose of sulfonylurea (or other concomitantly administered insulin secretagogue) or insulin.

Does Foundayo cause low blood sugar?

Its FDA label: Foundayo lowers blood glucose and can cause hypoglycemia. In a trial of adults with type 2 diabetes and BMI ≥27 kg/m 2 (Trial 2), hypoglycemia (plasma glucose <54 mg/dL) was reported in 2% of patients treated with orforglipron versus 0.2% of patients receiving placebo.

Does Trulicity cause low blood sugar?

Its FDA label: Patients receiving Trulicity in combination with an insulin secretagogue (e.g., sulfonylurea) or insulin may have an increased risk of hypoglycemia, including severe hypoglycemia. The risk of hypoglycemia may be lowered by a reduction in the dose of sulfonylurea (or other concomitantly administered insulin secretagogue) or insulin.

Does Saxenda cause low blood sugar?

Its FDA label: Adult patients with type 2 diabetes mellitus on an insulin secretagogue (e.g., sulfonylurea) or insulin may have an increased risk of hypoglycemia with use of Saxenda, including severe hypoglycemia. In patients with type 2 diabetes, monitor blood glucose prior to starting Saxenda and during Saxenda treatment.

Does Victoza cause low blood sugar?

Its FDA label: Adult patients receiving Victoza in combination with an insulin secretagogue (e.g., sulfonylurea) or insulin may have an increased risk of hypoglycemia, including severe hypoglycemia. In pediatric patients 10 years of age and older, the risk of hypoglycemia was higher with Victoza regardless of insulin and/or metformin use..

Trial rates describe groups, not what one person will feel. Talk to your clinician before starting, stopping or changing a medicine.

GLPcompare is an informational data platform, not a medical provider or pharmacy. Nothing here is medical advice, a diagnosis, or a recommendation to start, stop, or change any treatment. Data is aggregated from public sources and can be incomplete or out of date. Always confirm with a licensed clinician and the current FDA label.